The high rates of misdiagnosis and untreated mortality with regard to Budd-Chiari syndrome (BCS) indicated the need to screen effective biomarkers. The aim of this study was to explore the function of extracellular vesicles (EVs) in patients with BCS as well as associated mechanisms. First, differentially expressed long non-coding RNAs (lncRNAs) from EVs separated from serum between BCS and healthy controls were screened using microarray analysis. Second, the proliferation, migration and tube formation of human vascular endothelial cells (HUVECs) were detected after EVs treatment, along with vascular endothelial growth factor (VEGF) levels and inflammatory factors from the cell supernatant. Last, the overexpressed lncRNA was transfected into the cells to further explore the mechanisms involved. Extracellular vesicles of BCS patients have significantly higher levels of lncRNA MTUS2-5 than healthy controls. Apparently, treatment with EVs from BCS or the ones transfected with plasmids that overexpress lncRNA MTUS2-5 enhances proliferation, migration and angiogenesis capacity. The results were considerably better than those obtained from treatment with EVs from healthy controls or transfection with the normal control plasmid, which also elevated the level of VEGF and inflammatory factors. Furthermore, FOS and PTGS2 were potentially regulated by the lncRNA MTUS2-5 transmitted by EVs. The lncRNA MTUS2-5 in EVs plays an important role in angiogenesis in the Budd-Chiari syndrome.

颈动脉狭窄(carotid artery stenosis,CS)是指多种原因造成颈动脉的狭窄,导致脑供血不足,甚至出现缺血性脑卒中的临床症候群.动脉粥样硬化是颈动脉狭窄的主要病因.随着影像技术不断进步,CS的诊断及评估更加精准.腔内技术的进展,也为CS的诊治提供新思路.本文结合国内外相关文献,就颅外颈动脉粥样硬化性狭窄的诊疗进展作一综述.

回顾性分析32例主动脉分叉覆膜支架腔内重建治疗TASCⅡD型主髂动脉闭塞症患者的近中期疗效。治疗技术成功率为100％，术后并发症率为6.25％，均无围手术期死亡，5例发生了支架内再闭塞（15.6％）。全因死亡率为0，12个月和24个月的一期通畅率分别为87.5％、84.38％，二期通畅率均为100％。本研究显示主动脉分叉覆膜支架腔内重建技术治疗 TASCⅡD型主髂动脉闭塞性疾病是安全、有效的，并可获得满意的近中期通畅率。